Clinical Trial Update: Triplet (FOLFOXIRI) vs. Doublet (FOLFOX or FOLFIRI) Regimen as a 1st Line Treatment in Metastatic Colorectal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial comparing triplet FOLFOXIRI to doublet FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• FOLFOX
• FOLFOXIRI (folinic acid (leucovorin), fluorouracil (5-FU), oxaliplatin, irinotecan)

Snippet

Sponsor: Kasr El Aini Hospital | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED